GlassScriptPhysician profile
Katie R Owens
NPI 1932403581
$1,290.97
in general payments reported to CMS, 2019-2025
21 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.51 · 2022: $31.24 · 2023: $346 · 2024: $494 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $358.39 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.23 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $87.05 | 2023-2024 | Verquvo, Winrevair |
| Pfizer INC. | $75.15 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $73.54 | 2024 | |
| Novo Nordisk INC | $67.49 | 2024-2025 | Wegovy |
| Philips North America LLC | $63.57 | 2023-2024 | (Ck4) Mcot |
| Janssen Pharmaceuticals, INC | $59.98 | 2023 | Xarelto |
| Kestra Medical Technology Services, INC. | $57.51 | 2025 | Assure Wcd |
| Lilly USA, LLC | $52.66 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $42.55 | 2025 | |
| Amgen INC. | $36.91 | 2021-2024 | |
| Actelion Pharmaceuticals US, INC. | $32.49 | 2023 | Opsumit |
| Novartis Pharmaceuticals Corporation | $22.63 | 2025 | |
| Baxter Healthcare | $21.43 | 2023 | Preveleak |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $20.95 | 2023 | Tyvaso |
| Abiomed | $19.24 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $17.54 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.05 | 2023 | Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $15.95 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $15.66 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.